glycine has been researched along with Activated Protein C Resistance in 2 studies
Activated Protein C Resistance: A hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). The activated form of Factor V (Factor Va) is more slowly degraded by activated protein C. Factor V Leiden mutation (R506Q) is the most common cause of APC resistance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The composite endpoint of screened deep vein thrombosis (DVT) and symptomatic pulmonary embolism (PE) during prophylaxis did not differ significantly between patients with or without these mutations." | 2.70 | Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. ( Andersson, C; Bylock, A; Eriksson, BI; Frison, L; Gustafsson, D; Larson, G; Lindahl, TL; Wåhlander, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Larsen, TB | 1 |
| Lassen, JF | 1 |
| Dahler-Eriksen, BS | 1 |
| Petersen, PH | 1 |
| Brandslund, I | 1 |
| Wåhlander, K | 1 |
| Larson, G | 1 |
| Lindahl, TL | 1 |
| Andersson, C | 1 |
| Frison, L | 1 |
| Gustafsson, D | 1 |
| Bylock, A | 1 |
| Eriksson, BI | 1 |
1 trial available for glycine and Activated Protein C Resistance
| Article | Year |
|---|---|
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.
Topics: Activated Protein C Resistance; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthropl | 2002 |
1 other study available for glycine and Activated Protein C Resistance
| Article | Year |
|---|---|
Effect of anticoagulant therapy on the hypercoagulable state in patients carrying the factor V Arg506Gln mutation.
Topics: Activated Protein C Resistance; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arginine | 1998 |